Literature DB >> 15832191

Nuclear galectin-3 expression is an independent predictive factor of recurrence for adenocarcinoma and squamous cell carcinoma of the lung.

Anne Mathieu1, Isabelle Saal, Aline Vuckovic, Valérie Ransy, Pierre Vereerstraten, Herbert Kaltner, Hans-Joachim Gabius, Robert Kiss, Christine Decaestecker, Isabelle Salmon, Myriam Remmelink.   

Abstract

The tumor stage is the most powerful prognostic tool for predicting the survival rates of lung carcinoma patients. However, prognosis of individual patients is difficult in part because of the marked clinical heterogeneity among such patients. Galectins are involved in cell growth, apoptosis and cell migration features, and their diagnostic and prognostic values have already been demonstrated in various types of cancers. In the present paper we analyze the potential prognostic value of immunohistochemical galectin-3 expression in lung adenocarcinomas and squamous cell carcinomas. In all, 165 squamous cell carcinomas and 121 adenocarcinomas were immunostained for galectin-3. In each case the immunohistochemical analyses consisted of an evaluation of the percentage of tumor cells stained and the intensity of staining. An IP score (ie Intensity x Percentage) was thus determined for each lung carcinoma. A large majority of cases displayed galectin-3 expression. While the cytoplasmic staining in the squamous cell carcinomas was focal and moderately intense, the staining in the adenocarcinomas was diffuse and intense. The IP scores were significantly (P=0.0001) higher in the adenocarcinomas than in the squamous cell carcinomas. The difference in nuclear expression profiles between the two cancer types was statistically significant (P=0.0005). Cox multivariate analysis carried out on the patients' genders, the TNM classification and the galectin-3-related variables showed that of the galectin-3-related variables, only the nuclear location of galectin-3 was identified as a prognostic indicator of recurrence independent of the clinicopathological features characterizing the patients (P=0.02). The prognostic contribution of this latter variable was enhanced when the patients with relapse-free follow-ups longer than 8 months were considered (P=0.005). Galectin-3 immunohistochemical expression differs between squamous cell carcinomas and adenocarcinomas, but the nuclear expression of galectin-3 behaves as a significant prognostic predictor for all the cases as a group.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15832191     DOI: 10.1038/modpathol.3800416

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  18 in total

1.  Galectin-1, -3, -7 expressions in congenital and acquired pediatric cholesteatomas compared to external auditory canal skin.

Authors:  Marc Vander Ghinst; Myriam Remmelink; Anne-Laure Mansbach; Sergio Hassid; Georges Choufani
Journal:  Clin Exp Otorhinolaryngol       Date:  2012-06-12       Impact factor: 3.372

Review 2.  Nuclear transport of galectin-3 and its therapeutic implications.

Authors:  Tatsuyoshi Funasaka; Avraham Raz; Pratima Nangia-Makker
Journal:  Semin Cancer Biol       Date:  2014-03-19       Impact factor: 15.707

3.  Predictive importance of galectin-3 for recurrence of non-small cell lung cancer.

Authors:  Yoko Kataoka; Tomoyuki Igarashi; Yasuhiko Ohshio; Takuya Fujita; Jun Hanaoka
Journal:  Gen Thorac Cardiovasc Surg       Date:  2019-03-22

4.  Predictive role of galectin-3 for immune checkpoint blockades (ICBs) in advanced or metastatic non-small cell lung cancer: a potential new marker for ICB resistance.

Authors:  Jung Sun Kim; Soyeon Kim; Jaemoon Koh; Miso Kim; Bhumsuk Keam; Tae Min Kim; Bertil Lindmark; Dong-Wan Kim
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-17       Impact factor: 4.322

5.  Targeted disruption of the galectin-3 gene results in decreased susceptibility to NNK-induced lung tumorigenesis: an oligonucleotide microarray study.

Authors:  Hekmat Osman Abdel-Aziz; Yoshihiro Murai; Ichiro Takasaki; Yoshiaki Tabuchi; Hua-chuan Zheng; Kazuhiro Nomoto; Hiroyuki Takahashi; Koichi Tsuneyama; Ichiro Kato; Daniel K Hsu; Fu-tong Liu; Koichi Hiraga; Yasuo Takano
Journal:  J Cancer Res Clin Oncol       Date:  2008-01-17       Impact factor: 4.553

Review 6.  The emerging role of galectins in high-fatality cancers.

Authors:  Cherylane Dubé-Delarosbil; Yves St-Pierre
Journal:  Cell Mol Life Sci       Date:  2017-11-08       Impact factor: 9.261

Review 7.  Regulation of cancer-related gene expression by galectin-3 and the molecular mechanism of its nuclear import pathway.

Authors:  Susumu Nakahara; Avraham Raz
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

8.  Galectin-3 and cyclin D1 expression in non-small cell lung cancer.

Authors:  Monika Kosacka; Paweł Piesiak; Aneta Kowal; Marcin Gołecki; Renata Jankowska
Journal:  J Exp Clin Cancer Res       Date:  2011-10-24

9.  Prognostic significance of galectin-3 expression in patients with resected NSCLC treated with platinum-based adjuvant chemotherapy.

Authors:  Seiichiro Kusuhara; Satoshi Igawa; Masaaki Ichinoe; Ryo Nagashio; Yuki Kuchitsu; Yasuhiro Hiyoshi; Kazu Shiomi; Yoshiki Murakumo; Makoto Saegusa; Yukitoshi Satoh; Yuichi Sato; Katsuhiko Naoki
Journal:  Thorac Cancer       Date:  2021-04-01       Impact factor: 3.500

10.  An automated blur detection method for histological whole slide imaging.

Authors:  Xavier Moles Lopez; Etienne D'Andrea; Paul Barbot; Anne-Sophie Bridoux; Sandrine Rorive; Isabelle Salmon; Olivier Debeir; Christine Decaestecker
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.